Previous 10 | Next 10 |
Halozyme Therapeutics (NASDAQ:HALO): Non-GAAP EPS of $0.55 beats by $0.07; GAAP EPS of $1.48 beats by $1.06. Revenue of $115.83M beats by $9.99M. Press Release Guidance Revenues of $430 million to $445 million, increased from prior guidance of $425 million to $445 million, representing year-o...
Halozyme To Host Third Quarter 2021 Financial Results Webcast and Conference Call PR Newswire SAN DIEGO , Oct. 19, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2021 on...
Small Pharma Analyst is a veteran of the pharma industry and specializes in the analysis of small pharma companies. The opportunity in small-caps, leveraging their industry experience to gain an edge and how to find catalysts are topics discussed. Small Pharma Analyst shares a lon...
Low risk biotech with steadily increasing revenue and earnings from ENHANZE drug delivery. Revenue and earnings are expected to peak at end of the decade with a long tail into the mid-2030s. Sizeable earnings provide ample cash for acquisitions or partnerships that will likely kee...
Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference PR Newswire SAN DIEGO , Sept. 15, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Elaine Sun , senior vice president and chief financial ...
Fundamental Research Corp has issued a report entitled "Halo Collective Inc.(NEO: HALO / OTCQX: HCANF / GERMANY: A9KN) Q2 Revenue up 74% YoY / Spin-Off Transaction to Be a Catalyst" and dated August 27, 2021. To read a summary of the key highlights, or to login and download the full analyst r...
Halozyme to Present at Wells Fargo 2021 Virtual Healthcare Conference PR Newswire SAN DIEGO , Aug. 26, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive officer, will pre...
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Halozyme Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. Halozyme Therapeutics, inc (NASDAQ: HALO) Q2 2021 Earnings Call Aug 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcrip...
Halozyme Therapeutics, Inc. (HALO) Q2 2021 Earnings Conference Call August 09, 2021, 04:30 PM ET Company Participants Al Kildani - Vice President of Investor Relations and Corporate Communications Helen Torley - President and CEO Elaine Sun - CFO Conference Call Participants Charles Duncan - ...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...